Telix Pharmaceuticals Ltd. (AU:TLX) has released an update.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Telix Pharmaceuticals has received FDA Fast Track designation for its brain cancer imaging agent TLX101-CDx, aimed at improving glioma diagnosis and management. The company has also announced a collaboration with UCSF for joint development and commercialization, as well as a partnership with PharmaLogic for manufacturing and distribution in the U.S. market, with the goal of making the advanced imaging agent widely available to patients upon regulatory approval.
For further insights into AU:TLX stock, check out TipRanks’ Stock Analysis page.